Significance of monitoring imatinib plasma concentration in second-line treatment decisions for <i>c-kit 11</i> gene-mutated gastrointestinal stromal tumors
Increasing IM dosage for c-kit 11-mutated advanced GISTs post-IM failure may prolong OS if plasma concentration is < 1100 ng/mL. Switching tyrosine kinase inhibitors may improve DCR and PFS if ≥ 1100 ng/mL.
Authors
- Yongle Du (ORCID: https://orcid.org/0000-0001-5668-4710)
- Haitao Li (ORCID: https://orcid.org/0000-0003-1050-5494)
- Jinjin Li (ORCID: https://orcid.org/0000-0001-5434-3672)
- Zhen Huang (ORCID: https://orcid.org/0009-0009-3553-3361)
- Jun Zhang (ORCID: https://orcid.org/0000-0003-3708-9603)
Institutions
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- World Journal of Gastrointestinal Oncology
- Published
- 2025-02-13
- DOI
- https://doi.org/10.4251/wjgo.v17.i3.98746
- Citations
- 1
- Primary Topic
- Gastrointestinal Tumor Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.81